Guo YR, Liu XM, Wang GX. Exposure to proton pump inhibitors and risk of diabetes: A systematic review and meta-analysis. World J Diabetes 2023; 14(2): 120-129 [PMID: 36926660 DOI: 10.4239/wjd.v14.i2.120]
Corresponding Author of This Article
Gui-Xia Wang, MD, PhD, Professor, Department of Endocrinology and Metabolism, The First Hospital of Jilin University, No. 71 Xinmin Street, Changchun 130000, Jilin Province, China. gwang168@jlu.edu.cn
Research Domain of This Article
Endocrinology & Metabolism
Article-Type of This Article
Meta-Analysis
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Diabetes. Feb 15, 2023; 14(2): 120-129 Published online Feb 15, 2023. doi: 10.4239/wjd.v14.i2.120
Exposure to proton pump inhibitors and risk of diabetes: A systematic review and meta-analysis
Yun-Ran Guo, Xin-Ming Liu, Gui-Xia Wang
Yun-Ran Guo, Xin-Ming Liu, Gui-Xia Wang, Department of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun 130000, Jilin Province, China
Author contributions: Guo YR and Wang GX contributed to the study design; Guo YR and Liu XM conducted data collection and selection; Guo YR performed data analysis and wrote the manuscript; All authors read and approved the final manuscript.
Conflict-of-interest statement: The authors declare that there are no conflicts of interest to report.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Gui-Xia Wang, MD, PhD, Professor, Department of Endocrinology and Metabolism, The First Hospital of Jilin University, No. 71 Xinmin Street, Changchun 130000, Jilin Province, China. gwang168@jlu.edu.cn
Received: November 26, 2022 Peer-review started: November 26, 2022 First decision: December 12, 2022 Revised: December 20, 2022 Accepted: January 19, 2023 Article in press: January 19, 2023 Published online: February 15, 2023
ARTICLE HIGHLIGHTS
Research background
There is a still controversial connection between the widespread use of proton pump inhibitors (PPIs) and the risk of diabetes.
Research motivation
In a previous meta-analysis, the use of PPIs was shown to not be associated with the risk of diabetes. However, three recent high-quality studies found that the use of PPIs was associated with an increased risk of diabetes. Therefore, a meta-analysis was carried out to determine the association between PPIs and diabetes.
Research objectives
To provide more reliable evidence on the relationship between PPI use and diabetes risk.
Research methods
Meta-analysis was used to realize the objectives. Statistical analyses were performed by using Stata version 15.0.
Research results
Results showed that the use of PPIs increased the risk of diabetes (odds ratio = 1.23, 95% confidence interval: 1.05-1.43, n = 9, I2 = 96.3%). In the subgroup analysis, geographic location and study type had significant effects on the overall results. No publication bias (P > 0.05) was found in Egger’s or Begg’s tests. Also, sensitivity analysis confirmed the stability of the results.
Research conclusions
The results of this study indicated that the use of PPIs was associated with an increased risk of diabetes.
Research perspectives
It is expected that more research from diverse geographic locations with detailed data on the use of PPIs is required in the future.
